News

Part I of the CPHI Annual Report looks ahead at the potential for biologics outsourcing and contract manufacturing organisations (CMOs) in 2023 in advance of CPHI Frankfurt, the largest pharma event in the world, which will be held at...

According to a new report by IPPR, the UK's percentage of worldwide research and development (R&D) spending has decreased by 5% since 2014. Even while successive prime leaders, from David Cameron's jewel in the crown to Boris Johnson's science...

The necessity to update and alter the FDA's now-contentious rapid approval strategy is highlighted by the protracted, complicated FDA process to discontinue commercialization of medications that do not demonstrate safety and efficacy in mandated post-approval confirmatory studies. Over the...

Andelyn Biosciences, Inc., a world-leading gene therapy CDMO, announced the addition of a new GMP clinical and commercial manufacturing facility, the  Andelyn Corporate Center (ACC), to its network of flexible and scalable sites that  support cell and gene therapy...

Prescriptions are quite expensive, and when you might need them to function at your best and to survive, it gets difficult to keep buying them at a very high cost. Medicines can be costly with insurance and when a...

According to data from the U.S. Department of Veterans Affairs (VA), a reduction in prostate cancer screening has been associated with a subsequent rise in advanced malignancies. These findings may prompt a review of the country's current testing recommendations....

Researchers discovered that by turning off the function of two genes, stomach tumours can become resistant to ATR inhibitors. As a result, genetic screening tests may one day be used to identify patients with cancers that are most likely...